Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02713178 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty
A Phase 3 study of Pain, sponsored by Pacira Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 232
- Enrollment target
- 17
- Study locations
NCT02713178: Completed Phase 3 study of Pain, sponsored by Pacira Pharmaceuticals.
NCT02713178 is a Phase 3 study of Pain that has completed, run by Pacira Pharmaceuticals. The registered enrollment target is 232 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (24% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02713178, a Phase 3 study of Pain, has completed, sponsored by Pacira Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 232 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in 232 adult subjects undergoing primary unilateral TKA under general or spinal anesthesia.
Primary Outcome
AUC of VAS pain intensity scores through 72 hours. Visual Analog Scale (VAS) is a pain scale. The VAS was presented as a straight 10 cm line, where 0 cm is no pain and 10 cm is the worst pain possible. Patients were asked, "How much pain are you experiencing right now? Please place a vertical mark on the line below to indicate the level of pain you are experiencing right now."
Conditions Studied
Interventions
- DRUG Placebo
- DRUG bupivacaine liposome injectable suspension
Study Locations (17)
Pennsylvania
- Indiana Regional Medical Center - Indiana
- Thomas Jefferson University Hospital - Philadelphia
- Chan Soon-Shiong Medical Center - Windber
Other
- Ziekenhuis Oost-Limburg - Genk
- Aarhus University Hospital - Aarhus C
- Regionshospital Silkeborg - Silkeborg
Florida
- Jackson Memorial Hospital/University of Miami - Miami
- Pensacola Research Associates - Pensacola
Massachusetts
- Brigham and Women's Hospital - Boston
- Massachusetts General Hospital - Boston
Texas
- Hermann Drive Surgical Hospital - Houston
- Westside Surgical Hospital - Houston
Alabama
- Horizon Research Group, Inc - Mobile
Colorado
- Denver Metro Orthopedics - Englewood
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 232 participants |
| Start Date | 2016-06-03 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 3 |
What the finished NCT02713178 record still lists
NCT02713178 is an interventional study that assigns participants to a tested intervention. The registered 232 participants enrollment target is mid-sized for trials with a published cap, below the 304-participant average among 374 other Pain trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02713178 lists 17 locations in 10 states (Pennsylvania, Other, Florida).
Frequently Asked Questions
What is clinical trial NCT02713178 about?
NCT02713178 is a clinical study titled "Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty". This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in 232 adult subjects undergoing primary unilateral TKA under general or spinal anesthesia.
What is the current status of trial NCT02713178?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 232 participants. The study started on 2016-06-03. Estimated completion is 2017-06-30.
What conditions does trial NCT02713178 study?
This clinical trial studies the following conditions: Pain.
What interventions are being tested in trial NCT02713178?
The interventions under investigation include: Placebo (DRUG), bupivacaine liposome injectable suspension (DRUG).
Who is sponsoring clinical trial NCT02713178?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02713178 being conducted?
This trial has 17 study locations across Alabama, Colorado, Florida, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02713178's enrollment target sits among peer trials
232 78th of 374 higher than 297 of 374 other Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of NSAIDs on Union, Opioid Utilization and Pain Management for Tibia Fractures: A Pragmatic, Randomized Controlled Trial
RECRUITING · Phase 3
-
Opioid-Free Orthopaedics
RECRUITING · Phase 3
-
Suzetrigine in Total Hip Arthroplasty
RECRUITING · Phase 3
-
Optimizing Chronic Pain Care With Mindfulness and Chronic Pain Management Visits
RECRUITING · Phase 3
-
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
RECRUITING · Phase 3
-
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01356290 · 232 participants · Phase 2
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
- NCT04753359 · 232 participants · NA
Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer
- NCT04770870 · 232 participants · NA
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
- NCT05948943 · 232 participants · Phase 2
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI